Sab Biotherapeutics Inc (SABS) — Who's Buying and Selling (13F, Q2 2026)

SABS ranks #4873 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

88 institutions disclose a position in SABS, but none treat it as a major bet — even Vivo Capital, LLC, its most concentrated holder, allocates just 2.6% of its own portfolio to it.

Perceptive Advisors LLC has added to its SABS position for two straight quarters, increasing it by $22.8M to reach $25.8M today.

Simplify Asset Management Inc. has trimmed its SABS position for two straight quarters, cutting it by $369.9K while still holding $408.9K.

SABS is up 1.8% today, and institutions have been net buyers of $15.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

SABS reported a net loss of $12.8M over the trailing twelve months.

• Not yet profitable — net loss of $12.8M over the trailing twelve months
• Revenue declined 40.9% year over year
• Net income improved year over year, from -$37.1M to -$12.8M
• Operating cash flow was negative, using $44.8M in cash
• Current ratio of 9.46x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.14x equity — within a conventional range